Article Sidebar
Published:
Jun 9, 2023DOI:
10.4314/tjpr.v22i2.4Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
IFI6 predicts prognosis and promotes cell growth of human colorectal cancer
Abstract
Purpose: To analyze the effect of IFI6 in colorectal cancer (CRC).
Methods: Differentially-expressed genes were analyzed using a volcano plot. Metascape and STRING were used for functional enrichment and protein-protein interaction network analyses, respectively. Expression of IFI6 was analyzed using the online platforms TIMER, UALCAN, and GEPIA. The correlation between IFI6 and poor prognosis was analyzed using prognoscan, while Western blotting was used to determine the expressions of related proteins. Cell proliferation was performed by CCK8 and foci formation assays. Cell apoptosis was assessed using flow cytometry.
Results: Differentially-expressed genes between CRC cells and alisertib-resistant CRC cells comprised 84 upregulated genes and 358 downregulated genes (p < 0.05). Enrichment analysis showed that differential genes were mainly involved in interferon α/β signaling, antiviral mechanism of interferon-stimulated genes, and positive regulation of the immune response. IFI6, a hubgene in the protein-protein interaction network, was highly expressed in CRC (p < 0.001) and correlated with poor prognoses (p = 0.028). IFI6 knockdown inhibited cell viability and colony formation and induced cell apoptosis by upregulation of p53, p21, and Bax.
Conclusion: These results suggest that IFI6 may be a biomarker for the diagnosis of human CRC.
